GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange about change in Management
GLAXO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.2 pts more than Nifty Midcap 150 and 0.3 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
GlaxoSmithKline Pharmaceuticals announced a change in its top finance leadership. The current CFO and Whole-Time Director, Mr. Juby Chandy, will step down from both roles effective March 11, 2026, to take up a new role leading APAC Finance within the GSK Group. In his place, Mr. Ronojit Biswas (DIN 07684843) has been appointed as the new Whole-Time Director & CFO for a three-year term starting April 1, 2026. Ronojit is a GSK veteran with over 25 years of experience across India, Vietnam, Singapore, Brazil, and the UK, and most recently served as Senior Finance Director – Global Product Strategy in Singapore. The company acknowledged Chandy's contributions in strengthening the financial position and governance during his tenure.
This is a smooth, internally managed CFO transition within the GSK Group with no governance red flags, likely to be neutral to mildly positive as the incoming CFO is a seasoned insider. Shareholders should note a brief overlap period between March 11 and April 1 when the CFO position will be vacant.